Simojoki Marja, Santala Markku, Risteli Juha, Kauppila Antti
Department of Obstetrics and Gynecology, University of Oulu, FIN-90220, Oulu, Finland.
Gynecol Oncol. 2003 Mar;88(3):358-62. doi: 10.1016/s0090-8258(02)00139-7.
The metabolism and prognostic value of serum concentrations of the aminoterminal (PINP) and carboxyterminal (PICP) propeptides of type I collagen and the PICP:PINP ratio in relation to the carboxyterminal telopeptide of type I collagen (ICTP) in ovarian cancer were evaluated.
Fifty patients with epithelial ovarian cancer were evaluated with serial measurements of serum concentrations of PICP, PINP, and ICTP before the operation and at 3-month intervals during the first year after the operation. For statistical analysis the patients were divided into two groups according to clinical outcome (alive vs dead) and clinical behavior (fast progression vs others).
The serum PINP concentration before the operation was increased and the PICP/PINP ratio was lowered in patients with poor prognosis (PP) compared to those with good prognosis (GP) and in patients with fast progression compared to others. The serum PICP concentration did not differ between the groups. The circulating ICTP concentration was significantly higher in the PP-group than in the GP group. In Kaplan-Meier analysis the PICP:PINP ratio divided the PP and GP patients (P = 0.0004). In multivariate regression analysis, the independent prognostic variables were clinical stage (P = 0.014, 95% confidence interval (CI) 1.31-11.19) and preoperative serum ICTP concentration (P = 0.048, CI 1.01-5.91). When serum ICTP concentration was excluded from the equation, the PICP:PINP ratio (P = 0.012, CI 1.29-7.83), together with clinical stage (P = 0.013, CI 1.31-10.37), was found to be an independent prognostic variable. When the early and advanced stage patients were analyzed separately, the PICP:PINP ratio was a significant prognostic variable in multivariate analysis in early stage patients and in advanced stages during the first 4 years of follow-up.
A low PICP:PINP ratio was associated with fast progression and poor clinical outcome in ovarian cancer. Evaluation of the PICP:PINP ratio together with ICTP may be valuable in predicting the clinical outcome of ovarian cancer.
评估I型胶原蛋白氨基端(PINP)和羧基端(PICP)前体肽的血清浓度代谢及预后价值,以及I型胶原蛋白羧基端端肽(ICTP)与卵巢癌中PICP:PINP比值的关系。
对50例上皮性卵巢癌患者在手术前及术后第一年每3个月进行一次血清PICP、PINP和ICTP浓度的连续测量。为进行统计分析,根据临床结局(存活与死亡)和临床行为(快速进展与其他情况)将患者分为两组。
与预后良好(GP)的患者相比,预后不良(PP)的患者术前血清PINP浓度升高,PICP/PINP比值降低;与其他患者相比,快速进展的患者也是如此。两组间血清PICP浓度无差异。PP组的循环ICTP浓度显著高于GP组。在Kaplan-Meier分析中,PICP:PINP比值可区分PP组和GP组患者(P = 0.0004)。在多因素回归分析中,独立的预后变量为临床分期(P = 0.014,95%置信区间(CI)1.31 - 11.19)和术前血清ICTP浓度(P = 0.048,CI 1.01 - 5.91)。当血清ICTP浓度从方程中排除时,发现PICP:PINP比值(P = 0.012,CI 1.29 - 7.83)与临床分期(P = 0.013,CI 1.31 - 10.37)一起是独立的预后变量。当分别分析早期和晚期患者时,PICP:PINP比值在早期患者的多因素分析中以及随访的前4年中晚期患者的多因素分析中都是显著的预后变量。
低PICP:PINP比值与卵巢癌的快速进展和不良临床结局相关。联合评估PICP:PINP比值和ICTP可能对预测卵巢癌的临床结局有价值。